Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avdoralimab (Primary) ; Durvalumab (Primary)
  • Indications Liver cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Registrational
  • Acronyms STELLAR-001
  • Sponsors Innate Pharma

    • Most Recent Events

    • 08 Mar 2022 Results (n=46) presented at the 20th International Congress on Targeted Anticancer Therapies
    • 08 Sep 2020 Status changed from recruiting to discontinued, according to an Innate Pharma media release.
    • 08 Sep 2020 According to an Innate Pharma media release, Based on the data from our cohort expansions in NSCLC and IO-naive HCC, the Company has made the decision to stop enrollment in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top